LABELS · 3a7a4ad7-90ca-4d84-92f1-c61032067deb

Cyclophosphamide

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2024-12-30
Captured: 2026-09-09T23:37:44.904352+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult patients with: • malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s lymphoma, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma • multiple myeloma • leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) • mycosis fungoides (advanced disease) • neuroblastoma (disseminated disease) • adenocarcinoma of the ovary • retinoblastoma • carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. Limitations of Use This cyclophosphamide product is not indicated for use in pediatric patients due to the to the alcohol and propylene glycol content in this product. If treatment with cyclophosphamide is indicated in a pediatric patient, use a different cyclophosphamide product [see Warnings and Precautions ( 5.7 ), Use in Specific Populations ( 8.4 ), and Description ( 11 )] . Cyclophosphamide Injection is an alkylating drug indicated for treatment of adult patients with: Malignant Diseases: malignant lymphomas: Hodgkin’s lymphoma, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma. ( 1 ) Limitations of Use This cyclophosphamide product is not indicated for use in pediatric patients due to the alcohol and propylene glycol content in this product. If treatment with cyclophosphamide is indicated in a pediatric patient, use a different cyclophosphamide product. ( 1 )

Full extracted label fields

application numbers

NDA217150

boxed warning exact

brand names

Cyclophosphamide

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf2f4b95-0327-499a-a5a3-51b1bdef68c5

generic names

CYCLOPHOSPHAMIDE

3a7a4ad7-90ca-4d84-92f1-c61032067deb

indications and usage exact

1 INDICATIONS AND USAGE Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult patients with: • malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s lymphoma, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma • multiple myeloma • leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) • mycosis fungoides (advanced disease) • neuroblastoma (disseminated disease) • adenocarcinoma of the ovary • retinoblastoma • carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. Limitations of Use This cyclophosphamide product is not indicated for use in pediatric patients due to the to the alcohol and propylene glycol content in this product. If treatment with cyclophosphamide is indicated in a pediatric patient, use a different cyclophosphamide product [see Warnings and Precautions ( 5.7 ), Use in Specific Populations ( 8.4 ), and Description ( 11 )] . Cyclophosphamide Injection is an alkylating drug indicated for treatment of adult patients with: Malignant Diseases: malignant lymphomas: Hodgkin’s lymphoma, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma. ( 1 ) Limitations of Use This cyclophosphamide product is not indicated for use in pediatric patients due to the alcohol and propylene glycol content in this product. If treatment with cyclophosphamide is indicated in a pediatric patient, use a different cyclophosphamide product. ( 1 )

indications and usage tables exact

is original packager

true

manufacturer names

Sandoz Inc

matched search terms

carcinoma
lymphoma
lymphomas
leukemia
myeloma
malignant
neuroblastoma
retinoblastoma

package ndcs

0781-3528-75
0781-3528-10
0781-3529-70
0781-3529-10
0781-3530-80
0781-3530-10

product ndcs

0781-3528
0781-3529
0781-3530

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Dosage and Administration ( 2.2 ) 12/2024

record type

complete_spl_indications_section_candidate

routes

INTRAVENOUS

rxcuis

2679073

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00200.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA217150

brand names

Cyclophosphamide

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 324
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult patients with: • malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s lymphoma, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lym
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 0

current approval status

not_reconciled

duplicate text group

dup-00f00254442e61fcacf4

extraction review status

automated_candidate_pending_source_review

generic names

CYCLOPHOSPHAMIDE

ind-span-ce98782c629eb09305f9

label id

3a7a4ad7-90ca-4d84-92f1-c61032067deb

positive predicate support span

end: 82
end exclusive: true
exact text: is indicated
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 70

qualifier mentions

context exact
yclophosphamide Injection is indicated for the treatment of adult patients with:
kind
age
polarity
not_inferred
span
end
118
end exclusive
true
exact text
adult patients
label id
3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start
104

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 124
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult patients with:
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%223a7a4ad7-90ca-4d84-92f1-c61032067deb%22

spl effective date

2024-12-30

spl set id

cf2f4b95-0327-499a-a5a3-51b1bdef68c5

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · unclassified context

application numbers

NDA217150

brand names

Cyclophosphamide

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 529
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult patients with: • malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s lymphoma, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma • multiple myeloma • leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lympho
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 0

current approval status

not_reconciled

duplicate text group

dup-872df37bfc035a027f0a

extraction review status

automated_candidate_pending_source_review

generic names

CYCLOPHOSPHAMIDE

ind-span-7e199c65b113c225cdd4

label id

3a7a4ad7-90ca-4d84-92f1-c61032067deb

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 329
end exclusive: true
exact text: • malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s lymphoma, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 125

source url

https://api.fda.gov/drug/label.json?search=id%3A%223a7a4ad7-90ca-4d84-92f1-c61032067deb%22

spl effective date

2024-12-30

spl set id

cf2f4b95-0327-499a-a5a3-51b1bdef68c5

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA217150

brand names

Cyclophosphamide

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 548
end exclusive: true
exact text: ignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s lymphoma, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma • multiple myeloma • leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell)
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 130

current approval status

not_reconciled

duplicate text group

dup-8b4c3b1876da97be7773

extraction review status

automated_candidate_pending_source_review

generic names

CYCLOPHOSPHAMIDE

ind-span-859f5095fb9cd834ecc8

label id

3a7a4ad7-90ca-4d84-92f1-c61032067deb

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 348
end exclusive: true
exact text: • multiple myeloma
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 330

source url

https://api.fda.gov/drug/label.json?search=id%3A%223a7a4ad7-90ca-4d84-92f1-c61032067deb%22

spl effective date

2024-12-30

spl set id

cf2f4b95-0327-499a-a5a3-51b1bdef68c5

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA217150

brand names

Cyclophosphamide

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 839
end exclusive: true
exact text: tages III and IV of the Ann Arbor staging system), Hodgkin’s lymphoma, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma • multiple myeloma • leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) • mycosis fungoides (advanced disease) • neuroblastoma (disseminated disease) • adenocarcinoma of the ovary • retinoblastoma • carcinoma of the breast Cyclophosphamide, although effective alone in su
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 149

current approval status

not_reconciled

duplicate text group

dup-34515874c0807a87b169

extraction review status

automated_candidate_pending_source_review

generic names

CYCLOPHOSPHAMIDE

ind-span-f03183a15e5a106c2a33

label id

3a7a4ad7-90ca-4d84-92f1-c61032067deb

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 639
end exclusive: true
exact text: • leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration)
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 349

source url

https://api.fda.gov/drug/label.json?search=id%3A%223a7a4ad7-90ca-4d84-92f1-c61032067deb%22

spl effective date

2024-12-30

spl set id

cf2f4b95-0327-499a-a5a3-51b1bdef68c5

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

NDA217150

brand names

Cyclophosphamide

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 878
end exclusive: true
exact text: ffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) • mycosis fungoides (advanced disease) • neuroblastoma (disseminated disease) • adenocarcinoma of the ovary • retinoblastoma • carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequen
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 440

current approval status

not_reconciled

duplicate text group

dup-afc4f115dfdd9012f566

extraction review status

automated_candidate_pending_source_review

generic names

CYCLOPHOSPHAMIDE

ind-span-bce5a921127c54d526ab

label id

3a7a4ad7-90ca-4d84-92f1-c61032067deb

positive predicate support span

Source null

qualifier mentions

context exact
• mycosis fungoides (advanced disease)
kind
stage_or_setting
polarity
not_inferred
span
end
678
end exclusive
true
exact text
advanced disease)
label id
3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start
661

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 678
end exclusive: true
exact text: • mycosis fungoides (advanced disease)
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 640

source url

https://api.fda.gov/drug/label.json?search=id%3A%223a7a4ad7-90ca-4d84-92f1-c61032067deb%22

spl effective date

2024-12-30

spl set id

cf2f4b95-0327-499a-a5a3-51b1bdef68c5

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA217150

brand names

Cyclophosphamide

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 917
end exclusive: true
exact text: e myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) • mycosis fungoides (advanced disease) • neuroblastoma (disseminated disease) • adenocarcinoma of the ovary • retinoblastoma • carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially w
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 479

current approval status

not_reconciled

duplicate text group

dup-e8a648ae881185c5e8de

extraction review status

automated_candidate_pending_source_review

generic names

CYCLOPHOSPHAMIDE

ind-span-6ec3bf75a2eb42520c03

label id

3a7a4ad7-90ca-4d84-92f1-c61032067deb

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 717
end exclusive: true
exact text: • neuroblastoma (disseminated disease)
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 679

source url

https://api.fda.gov/drug/label.json?search=id%3A%223a7a4ad7-90ca-4d84-92f1-c61032067deb%22

spl effective date

2024-12-30

spl set id

cf2f4b95-0327-499a-a5a3-51b1bdef68c5

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA217150

brand names

Cyclophosphamide

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 947
end exclusive: true
exact text: cute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) • mycosis fungoides (advanced disease) • neuroblastoma (disseminated disease) • adenocarcinoma of the ovary • retinoblastoma • carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 518

current approval status

not_reconciled

duplicate text group

dup-f2e8c43e4b72fcde9775

extraction review status

automated_candidate_pending_source_review

generic names

CYCLOPHOSPHAMIDE

ind-span-4b4cc5d0801a0a5758a6

label id

3a7a4ad7-90ca-4d84-92f1-c61032067deb

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 747
end exclusive: true
exact text: • adenocarcinoma of the ovary
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 718

source url

https://api.fda.gov/drug/label.json?search=id%3A%223a7a4ad7-90ca-4d84-92f1-c61032067deb%22

spl effective date

2024-12-30

spl set id

cf2f4b95-0327-499a-a5a3-51b1bdef68c5

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

NDA217150

brand names

Cyclophosphamide

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 964
end exclusive: true
exact text: leukemia (cyclophosphamide given during remission is effective in prolonging its duration) • mycosis fungoides (advanced disease) • neuroblastoma (disseminated disease) • adenocarcinoma of the ovary • retinoblastoma • carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. Limitations of
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 548

current approval status

not_reconciled

duplicate text group

dup-e63e41f426282afeb048

extraction review status

automated_candidate_pending_source_review

generic names

CYCLOPHOSPHAMIDE

ind-span-ca4906260efd0db22b63

label id

3a7a4ad7-90ca-4d84-92f1-c61032067deb

positive predicate support span

Source null

qualifier mentions

context exact
• retinoblastoma
kind
biomarker
polarity
not_inferred
span
end
764
end exclusive
true
exact text
retinoblastoma
label id
3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start
750

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 764
end exclusive: true
exact text: • retinoblastoma
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 748

source url

https://api.fda.gov/drug/label.json?search=id%3A%223a7a4ad7-90ca-4d84-92f1-c61032067deb%22

spl effective date

2024-12-30

spl set id

cf2f4b95-0327-499a-a5a3-51b1bdef68c5

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

NDA217150

brand names

Cyclophosphamide

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1148
end exclusive: true
exact text: hosphamide given during remission is effective in prolonging its duration) • mycosis fungoides (advanced disease) • neuroblastoma (disseminated disease) • adenocarcinoma of the ovary • retinoblastoma • carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. Limitations of Use This cyclophosphamide product is not indicated for use in pediatric patients due to the to the alcohol and propylene glycol content in this product. If treatment with cyclophospham
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 565

current approval status

not_reconciled

duplicate text group

dup-6a4d36b6275f39df94cb

extraction review status

automated_candidate_pending_source_review

generic names

CYCLOPHOSPHAMIDE

ind-span-c3f7367ff2719b2113ee

label id

3a7a4ad7-90ca-4d84-92f1-c61032067deb

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 948
end exclusive: true
exact text: • carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs.
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 765

source url

https://api.fda.gov/drug/label.json?search=id%3A%223a7a4ad7-90ca-4d84-92f1-c61032067deb%22

spl effective date

2024-12-30

spl set id

cf2f4b95-0327-499a-a5a3-51b1bdef68c5

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · limitation of use

application numbers

NDA217150

brand names

Cyclophosphamide

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1316
end exclusive: true
exact text: retinoblastoma • carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. Limitations of Use This cyclophosphamide product is not indicated for use in pediatric patients due to the to the alcohol and propylene glycol content in this product. If treatment with cyclophosphamide is indicated in a pediatric patient, use a different cyclophosphamide product [see Warnings and Precautions ( 5.7 ), Use in Specific Populations ( 8.4 ), and Descri
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 749

current approval status

not_reconciled

duplicate text group

dup-c040866bb5d15ee7804e

extraction review status

automated_candidate_pending_source_review

generic names

CYCLOPHOSPHAMIDE

ind-span-cbc46f0c86f6cee797d3

label id

3a7a4ad7-90ca-4d84-92f1-c61032067deb

positive predicate support span

Source null

qualifier mentions

context exact
e This cyclophosphamide product is not indicated for use in pediatric patients due to the to the alcohol and propylene glycol content in t
kind
age
polarity
not_inferred
span
end
1044
end exclusive
true
exact text
pediatric patients
label id
3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start
1026

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1116
end exclusive: true
exact text: Limitations of Use This cyclophosphamide product is not indicated for use in pediatric patients due to the to the alcohol and propylene glycol content in this product.
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 949

source url

https://api.fda.gov/drug/label.json?search=id%3A%223a7a4ad7-90ca-4d84-92f1-c61032067deb%22

spl effective date

2024-12-30

spl set id

cf2f4b95-0327-499a-a5a3-51b1bdef68c5

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 11 · positive indication candidate

application numbers

NDA217150

brand names

Cyclophosphamide

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
positive_statement_also_contains_qualification_review_required

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1531
end exclusive: true
exact text: ith other antineoplastic drugs. Limitations of Use This cyclophosphamide product is not indicated for use in pediatric patients due to the to the alcohol and propylene glycol content in this product. If treatment with cyclophosphamide is indicated in a pediatric patient, use a different cyclophosphamide product [see Warnings and Precautions ( 5.7 ), Use in Specific Populations ( 8.4 ), and Description ( 11 )] . Cyclophosphamide Injection is an alkylating drug indicated for treatment of adult patients with: Malignant Diseases: malignant lymphomas: Hodgkin’s lymphoma, lymphocytic lymphoma, mixed-cell type lym
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 917

current approval status

not_reconciled

duplicate text group

dup-c09e70ad4b0416faf06c

extraction review status

automated_candidate_pending_source_review

generic names

CYCLOPHOSPHAMIDE

ind-span-be29f28ffb7254a12a7f

label id

3a7a4ad7-90ca-4d84-92f1-c61032067deb

positive predicate support span

end: 1164
end exclusive: true
exact text: is indicated
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 1152

qualifier mentions

context exact
If treatment with cyclophosphamide is indicated in a pediatric patient, use a different cyclophosphamide product [see Warn
kind
age
polarity
not_inferred
span
end
1179
end exclusive
true
exact text
pediatric
label id
3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start
1170

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1331
end exclusive: true
exact text: If treatment with cyclophosphamide is indicated in a pediatric patient, use a different cyclophosphamide product [see Warnings and Precautions ( 5.7 ), Use in Specific Populations ( 8.4 ), and Description ( 11 )] .
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 1117

source url

https://api.fda.gov/drug/label.json?search=id%3A%223a7a4ad7-90ca-4d84-92f1-c61032067deb%22

spl effective date

2024-12-30

spl set id

cf2f4b95-0327-499a-a5a3-51b1bdef68c5

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 12 · positive indication candidate

application numbers

NDA217150

brand names

Cyclophosphamide

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1901
end exclusive: true
exact text: th cyclophosphamide is indicated in a pediatric patient, use a different cyclophosphamide product [see Warnings and Precautions ( 5.7 ), Use in Specific Populations ( 8.4 ), and Description ( 11 )] . Cyclophosphamide Injection is an alkylating drug indicated for treatment of adult patients with: Malignant Diseases: malignant lymphomas: Hodgkin’s lymphoma, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma. ( 1 ) Limitations of Use This cyclophosphamide product is not indicated for use in pediatric patients due to the alcohol and propylene glycol content in this product. If treatment with cyclophosphami
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 1132

current approval status

not_reconciled

duplicate text group

dup-cab4dcb689a511b1c87f

extraction review status

automated_candidate_pending_source_review

generic names

CYCLOPHOSPHAMIDE

ind-span-c273a1afc2a092bd07b0

label id

3a7a4ad7-90ca-4d84-92f1-c61032067deb

positive predicate support span

end: 1390
end exclusive: true
exact text: is an alkylating drug indicated
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 1359

qualifier mentions

context exact
Injection is an alkylating drug indicated for treatment of adult patients with: Malignant Diseases: malignant lymphomas: Hodgkin’s ly
kind
age
polarity
not_inferred
span
end
1422
end exclusive
true
exact text
adult patients
label id
3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start
1408
context exact
Cyclophosphamide Injection is an alkylating drug indicated for treatment of adult patients with: Malignant Diseases: malignant lymphomas
kind
biomarker
polarity
not_inferred
span
end
1408
end exclusive
true
exact text
alkylating drug indicated for treatment of
label id
3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start
1365
context exact
mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma.
kind
biomarker
polarity
not_inferred
span
end
1682
end exclusive
true
exact text
retinoblastoma
label id
3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start
1668

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1701
end exclusive: true
exact text: Cyclophosphamide Injection is an alkylating drug indicated for treatment of adult patients with: Malignant Diseases: malignant lymphomas: Hodgkin’s lymphoma, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma.
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 1332

source url

https://api.fda.gov/drug/label.json?search=id%3A%223a7a4ad7-90ca-4d84-92f1-c61032067deb%22

spl effective date

2024-12-30

spl set id

cf2f4b95-0327-499a-a5a3-51b1bdef68c5

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 13 · limitation of use

application numbers

NDA217150

brand names

Cyclophosphamide

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1988
end exclusive: true
exact text: lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma. ( 1 ) Limitations of Use This cyclophosphamide product is not indicated for use in pediatric patients due to the alcohol and propylene glycol content in this product. If treatment with cyclophosphamide is indicated in a pediatric patient, use a different cyclophosphamide product. ( 1 )
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 1502

current approval status

not_reconciled

duplicate text group

dup-6a6daa76aebd089afe69

extraction review status

automated_candidate_pending_source_review

generic names

CYCLOPHOSPHAMIDE

ind-span-67d612f7dd1c309a59e3

label id

3a7a4ad7-90ca-4d84-92f1-c61032067deb

positive predicate support span

Source null

qualifier mentions

context exact
e This cyclophosphamide product is not indicated for use in pediatric patients due to the alcohol and propylene glycol content in this pro
kind
age
polarity
not_inferred
span
end
1803
end exclusive
true
exact text
pediatric patients
label id
3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start
1785

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1868
end exclusive: true
exact text: ( 1 ) Limitations of Use This cyclophosphamide product is not indicated for use in pediatric patients due to the alcohol and propylene glycol content in this product.
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 1702

source url

https://api.fda.gov/drug/label.json?search=id%3A%223a7a4ad7-90ca-4d84-92f1-c61032067deb%22

spl effective date

2024-12-30

spl set id

cf2f4b95-0327-499a-a5a3-51b1bdef68c5

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 14 · positive indication candidate

application numbers

NDA217150

brand names

Cyclophosphamide

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1988
end exclusive: true
exact text: etinoblastoma, breast carcinoma. ( 1 ) Limitations of Use This cyclophosphamide product is not indicated for use in pediatric patients due to the alcohol and propylene glycol content in this product. If treatment with cyclophosphamide is indicated in a pediatric patient, use a different cyclophosphamide product. ( 1 )
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 1669

current approval status

not_reconciled

duplicate text group

dup-90d205b461dd13580cf4

extraction review status

automated_candidate_pending_source_review

generic names

CYCLOPHOSPHAMIDE

ind-span-4ee1cff463cf255e7bab

label id

3a7a4ad7-90ca-4d84-92f1-c61032067deb

positive predicate support span

end: 1916
end exclusive: true
exact text: is indicated
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 1904

qualifier mentions

context exact
If treatment with cyclophosphamide is indicated in a pediatric patient, use a different cyclophosphamide product.
kind
age
polarity
not_inferred
span
end
1931
end exclusive
true
exact text
pediatric
label id
3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start
1922

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1982
end exclusive: true
exact text: If treatment with cyclophosphamide is indicated in a pediatric patient, use a different cyclophosphamide product.
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 1869

source url

https://api.fda.gov/drug/label.json?search=id%3A%223a7a4ad7-90ca-4d84-92f1-c61032067deb%22

spl effective date

2024-12-30

spl set id

cf2f4b95-0327-499a-a5a3-51b1bdef68c5

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 15 · unclassified context

application numbers

NDA217150

brand names

Cyclophosphamide

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1988
end exclusive: true
exact text: n pediatric patients due to the alcohol and propylene glycol content in this product. If treatment with cyclophosphamide is indicated in a pediatric patient, use a different cyclophosphamide product. ( 1 )
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 1783

current approval status

not_reconciled

duplicate text group

dup-3d60ec8aa9942e16a4d1

extraction review status

automated_candidate_pending_source_review

generic names

CYCLOPHOSPHAMIDE

ind-span-34bf96884f4cc0c4b22d

label id

3a7a4ad7-90ca-4d84-92f1-c61032067deb

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1988
end exclusive: true
exact text: ( 1 )
label id: 3a7a4ad7-90ca-4d84-92f1-c61032067deb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b640b4fabbd35c79eb6c5725d4f40525a0dca61c2113a251f9d2d876337e067c
start: 1983

source url

https://api.fda.gov/drug/label.json?search=id%3A%223a7a4ad7-90ca-4d84-92f1-c61032067deb%22

spl effective date

2024-12-30

spl set id

cf2f4b95-0327-499a-a5a3-51b1bdef68c5

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice